Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics: A One-Year Double-Blind Comparison in Multiple Episode Schizophrenics

Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics: A One-Year Double-Blind... Abstract • Sixty patients meeting the criteria established for schizophrenia who attained a clinical plateau following hospital discharge were randomized to receive for one year either penfluridol, 20 to 160 mg orally once each week, or fluphenazine decanoate, 0.5 to 4 ml every two weeks. The relapse rate for both treatments was low and equal. The rate of recurrence of psychosis for patients receiving penfluridol was 7% and for those receiving fluphenazine decanoate 10%. A retrospective comparison of the penfluridol group was made to a similar group of patients assigned to placebo in an earlier study. Placebo-treated patients had a relapse rate of 68%. Penfluridol patients had statistically fewer psychotic relapses. Questions about the possible carcinogenicity of penfluridol in animals will have to be resolved before it can be widely used. This study demonstrates the feasibility of using an oral, longacting antipsychotic agent. It would be a useful psychopharmacologic addition in the treatment of outpatient schizophrenics. References 1. Engelhardt DM, Freedman N, Rosen B, et al: Phenothiazines in prevention of psychiatric hospitalization: III. Delay or prevention of hospitalization . Arch Gen Psychiatry 11:162-169, 1964.Crossref 2. Leff JP, Wing JK: Trial of maintenance therapy in schizophrenia . Br Med J 3:599-604, 1971.Crossref 3. Hogarty GE, Goldberg SL, Schooler NR, et al: The collaborative study group: Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rates . Arch Gen Psychiatry 31:603-608, 1974.Crossref 4. Crawford R, Forrest A: Controlled trial of depot fluphenazine in outpatient schizophrenics . Br J Psychiatry 124:385-391, 1974.Crossref 5. Rifkin A, Quitkin F, Rabiner CJ, et al: Fluphenazine decanoate, oral fluphenazine and placebo in remitted schizophrenics . Arch Gen Psychiatry 34:43-47, 1977.Crossref 6. Gallant DM, Mielke DH, Spirtes MA, et al: Penfluridol: An efficacious long-acting oral antipsychotic . Am J Psychiatry 131:699-702, 1974. 7. Van Praag HM, Schut I, Dols, et al: Controlled trial of penfluridol in acute psychosis . Br Med J 4:710-713, 1971.Crossref 8. Cohen J: Statistical Power Analysis for the Behavioral Science . New York, Academic Press Inc, 1969. 9. Quitkin F, Rifkin A, Gochfeld L, et al: Tardive dyskinesia: Are first signs reversible? Am J Psychiatry 134:84-87, 1977. 10. Rifkin A, Quitkin F, Klein DF: Akinesia . Arch Gen Psychiatry 32:672-674, 1975.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of General Psychiatry American Medical Association

Long-Acting Oral vs Injectable Antipsychotic Drugs in Schizophrenics: A One-Year Double-Blind Comparison in Multiple Episode Schizophrenics

Loading next page...
 
/lp/american-medical-association/long-acting-oral-vs-injectable-antipsychotic-drugs-in-schizophrenics-a-P040ZN2ih6
Publisher
American Medical Association
Copyright
Copyright © 1978 American Medical Association. All Rights Reserved.
ISSN
0003-990X
eISSN
1598-3636
DOI
10.1001/archpsyc.1978.01770310095007
Publisher site
See Article on Publisher Site

Abstract

Abstract • Sixty patients meeting the criteria established for schizophrenia who attained a clinical plateau following hospital discharge were randomized to receive for one year either penfluridol, 20 to 160 mg orally once each week, or fluphenazine decanoate, 0.5 to 4 ml every two weeks. The relapse rate for both treatments was low and equal. The rate of recurrence of psychosis for patients receiving penfluridol was 7% and for those receiving fluphenazine decanoate 10%. A retrospective comparison of the penfluridol group was made to a similar group of patients assigned to placebo in an earlier study. Placebo-treated patients had a relapse rate of 68%. Penfluridol patients had statistically fewer psychotic relapses. Questions about the possible carcinogenicity of penfluridol in animals will have to be resolved before it can be widely used. This study demonstrates the feasibility of using an oral, longacting antipsychotic agent. It would be a useful psychopharmacologic addition in the treatment of outpatient schizophrenics. References 1. Engelhardt DM, Freedman N, Rosen B, et al: Phenothiazines in prevention of psychiatric hospitalization: III. Delay or prevention of hospitalization . Arch Gen Psychiatry 11:162-169, 1964.Crossref 2. Leff JP, Wing JK: Trial of maintenance therapy in schizophrenia . Br Med J 3:599-604, 1971.Crossref 3. Hogarty GE, Goldberg SL, Schooler NR, et al: The collaborative study group: Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rates . Arch Gen Psychiatry 31:603-608, 1974.Crossref 4. Crawford R, Forrest A: Controlled trial of depot fluphenazine in outpatient schizophrenics . Br J Psychiatry 124:385-391, 1974.Crossref 5. Rifkin A, Quitkin F, Rabiner CJ, et al: Fluphenazine decanoate, oral fluphenazine and placebo in remitted schizophrenics . Arch Gen Psychiatry 34:43-47, 1977.Crossref 6. Gallant DM, Mielke DH, Spirtes MA, et al: Penfluridol: An efficacious long-acting oral antipsychotic . Am J Psychiatry 131:699-702, 1974. 7. Van Praag HM, Schut I, Dols, et al: Controlled trial of penfluridol in acute psychosis . Br Med J 4:710-713, 1971.Crossref 8. Cohen J: Statistical Power Analysis for the Behavioral Science . New York, Academic Press Inc, 1969. 9. Quitkin F, Rifkin A, Gochfeld L, et al: Tardive dyskinesia: Are first signs reversible? Am J Psychiatry 134:84-87, 1977. 10. Rifkin A, Quitkin F, Klein DF: Akinesia . Arch Gen Psychiatry 32:672-674, 1975.Crossref

Journal

Archives of General PsychiatryAmerican Medical Association

Published: Jul 1, 1978

References